Can-Fite BioPharma Ltd.
CANF · AMEX
Company research
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an Israeli advanced clinical-stage biopharmaceutical company, incorporated in 1994 and headquartered in Ramat Gan, Israel, that specializes in developing orally bioavailable small molecule therapeutic products targeting oncological, liver, and inflammatory diseases, as well as erectile dysfunction. The company's platform technology leverages the A3 adenosine receptor (A3AR) as a therapeutic target, with its lead drug candidates Piclidenoson — currently advancing through a pivotal Phase III trial for psoriasis — and Namodenoson, which holds FDA Orphan Drug and Fast Track Designations and is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase IIb trial for metabolic-associated steatohepatitis (MASH), and a Phase IIa study in pancreatic cancer. A third candidate, CF602, is in preclinical development for erectile dysfunction, and the company also commercializes a predictive biomarker blood test kit for A3AR. Can-Fite maintains key strategic partnerships, including a licensing and collaboration agreement with CMS Medical for the development and commercialization of its lead candidates, and projects up to $685 million in future revenues upon regulatory approvals of its pipeline assets.
Research reports
H.C. Wainwright maintains a buy rating on CANF and raises its 12‑month price target from 5 to 8 dollars following positive Phase 2a data for namodenoson in advanced pancreatic ductal adenocarcinoma, highlighting achievement of the primary safety endpoint and durable survival outcomes. The note emphasizes strong investor enthusiasm after a 57% share price surge over the prior week, incorporation of PDAC cash flows into the valuation model, and continued confidence in the company’s late‑stage pipeline.
Timothy Sykes (TimothySykes.com) · June 27, 2026CANF Slides As Traders Weigh Weak Biotech FinancialsThis in‑depth trading and fundamental analysis characterizes CANF as a highly speculative micro‑cap biotech with negligible revenue, extremely weak profitability metrics, and distorted valuation ratios, concluding that risk/reward is unfavorable absent a major catalyst. The author details a clear downward technical trend, specific support and resistance levels (around 2.40 and 3.00 dollars) and a 3–6 month downside bias toward 2.00 dollars, framing CANF as an illiquid binary biotech option rather than a fundamentally backed investment.
H.C. Wainwright (via Investing.com) · May 11, 2026Can-Fite BioPharma stock price target raised to $5 by H.C. Wainwright on pet drug trialH.C. Wainwright reiterates its buy rating on CANF and lifts the price target from 2.50 to 5.00 dollars, citing the company’s ongoing Phase 2 study of piclidenoson for pet osteoarthritis and anticipated clinical data updates as key upside drivers. The report notes that despite severe share price drawdowns over the past year and six months, the firm’s 12‑month target reflects substantial potential appreciation for the ADRs based on pipeline progression and upcoming catalysts.
H.C. Wainwright (via Investing.com) · November 4, 2025H.C. Wainwright assumes coverage on Can-Fite BioPharma stock with Buy ratingIn this initiation note, H.C. Wainwright begins coverage of CANF with a buy rating and a 2.50‑dollar price target, arguing that the shares are significantly undervalued relative to its fair‑value model and trading near 52‑week lows. The analysis focuses on the company’s two late‑stage A3 adenosine receptor agonists, piclidenoson and namodenoson, the unique A3AR biology, favorable safety profile in over 1,600 patients, and de‑risked Phase 3 programs that underpin the positive risk‑reward thesis.